Home Add to Favorite Contact Submit  
           19 October, 2021


    
Category:  Press » Miscellaneous

 

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

Popularity:
         Views: 1478
2008-11-20 03:56:14     
The Debiopharm Group

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates, signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway. Utilising its know-how and fragment-based drug delivery technology platform, Aurigene has generated potent leads against the target. Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones. "We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work. The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies," said Rolland-Yves Mauvernay, President & Founder of Debiopharm Group. "Partnering with Debiopharm, a highly focused and successful drug development company, is highly synergistic for Aurigene, a drug discovery biotech. Aurigene has been collaborating with Debiopharm on two other programs for three years now, and the current licensing agreement with Debiopharm serves to reiterate the high quality of science and competence at Aurigene. This further strengthens the relationship between the companies," added CSN Murthy, CEO of Aurigene. About Debiopharm Group Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007. For more information on Debiopharm Group, please visit: http://www.debiopharm.com. About Aurigene Established in Bangalore, India, in 2002, Aurigene Discovery Technologies Ltd., is a drug discovery biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates in oncology, metabolic disorders and autoimmune diseases, with a proven track record of successful partnerships with big and medium-sized pharma and biotech companies globally. Aurigene has 10 drug discovery collaborations and a pipeline of 15 discovery programs at various stages, from Hit Generation to late-stage Pre-Clinical Optimization, and has filed 14 patents across 6 programs over the last 12 months. With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated operation with expertise in Hit Generation to Drug Development Candidates for IND nomination.

Debiopharm S.A. Contacts

Maurice Wagner

Director Corporate Affairs & Communications

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

Specialized in: Biopharmaceutical Development Partner - Global Biopharmaceutical Development - Development Of Innovative Molecules - Inlicensing Of Small Molecules - Financial And Managerial Responsability - Nrdo Company - Development Of Innovative Therapeutics - Expertise In P
URL: http://www.debiopharm.com
Print press release      Bookmark this page
Related Press releases 
Larson Electronics Releases Remote Control Light Tower with Dual HID Lamps (Popularity: ): KEMP, Texas, Feb. 11, 2013 -- Larson Electronics has announced today the release of the WAL-TP-2XGLM-H-1227 Portable Telescoping Light Tower with dual remote controlled HID spotlights designed for high power and easy deployment and operation. Featuring an adjustable tripod and dual magnetic mount remote control spotlights, this portable light tower is ideal for events and worksites where high output and easy deployment is desired.Larson Electronics' WAL-TP-2XGLM-H-1227 remote controlled dual spotlight ...
SmartBox LLC Launches Evolutionary Online Trading Strategies Platform (Popularity: ): Sep 24, 2012 - Los Angeles, CA: SmartBox LLC annouces today the official launch of TradeFollowr.com, an evolutionary trading strategies platform that allows users to follow and interact with thousands of automated trading systems and indicators in real time. Traders can share ideas though Twitter integration and the easy to use interface makes following the market moves fun and exciting.Brett Markinson, Founder and CEO of SmartBox LLC explains, "We are ...
Drinking Games Website Launches Despite Criticism (Popularity: ): NORTHPORT, Maine December 26, 2011 - Drinking Games - a new website about drinking entertainment launched this week by former US Navy Chief Jack O'Reilly, Ret., and former US Navy Fireman RJ Anayjuan, has already come under fire. The website owners say some have expressed doubt that anyone should be playing "drinking games" at all.   "I served 23 years in the Navy, and you can bet we did a lot of ...
The SI Names Brett Dody to Lead Intelligence Systems Group (Popularity: ): CHANTILLY, Va., Aug. 17, 2011 -- The SI Organization, Inc. (the SI) has named Brett Dody as the vice president of its Intelligence Systems Group.Dody joined the SI last year after retiring from government service, where he supported the Intelligence and Defense communities throughout his distinguished federal career. In his new role, he will oversee a line of business that supports Intelligence Community customer missions through systems integration and engineering ...
U.S. News Media Group Announces Most Connected Hospitals (Popularity: ): WASHINGTON, July 19, 2011 -- U.S. News Media Group today announced a list of the Most Connected Hospitals. The new list identifies U.S. News-ranked hospitals that are significantly advanced in the adoption of electronic medical record systems.We live in a digital age. We use electronic systems to connect with others, to entertain ourselves, and to compare the quality of myriad goods and services, including hospital care.Yet inside the walls of ...

Press release home snapshot 


Related Business 
Oncology Education Services, Inc. (Popularity: ): A for-profit subsidiary of the Oncology Nursing Society, develops oncology-related communication programs, products, and services for businesses and individuals working with oncology professionals
Pathway Communications (Popularity: ): Pathway Communications is a Canadian company and is part of the Pathway Group of Companies. The Pathway Group consists of Pathway Communications, CiteNet Internet, NetPulse Services and Teliuvo. Together, these companies offer a broad range of high-quality Managed Internet Services (DSL, Fibre based Solutions, Wireless and DSL based), Server Colocation, Web Hosting, VoIP and Long Distance Services.
Air Conditioning Services & Solutions (Popularity: ): Hill York’s Maintenance Agreement Program provides three solutions that are tailored specifically to the needs of our clients in different industries: Preventative Maintenance Agreement, Labor Maintenance Agreement and Certified Maintenance Agreement.
Selleck Chemicals (Popularity: ): Selleck Chemicals is one of the world leading suppliers of high-performance kinase inhibitors and antibodies for cell signaling and oncology research. Thousands of life-science reagents and reference compounds (inhibitor and antibody) for the non-clinical research fields.
Compromise Agreement Solicitors (Popularity: ): A Compromise Agreement is a common method of resolving an employment dispute without the need for legal proceedings. Our Compromise Agreement Solicitors offer the independent legal advice that is compulsory under the terms of a compromise agreement. One of our team will also put their name to a Compromise Agreement contract, a further requirement of a deal, proving both yourself and your employer have had separate legal advice in agreeing ...
Gilman Licensing Associates (Popularity: ): Licensing agent and consultant specializing in the development and management of brands as well as in expert witness and trademark valuation services.
Acrylic Sign Boards Supplier (Popularity: ): A well established manufacturing & supplying company of acrylic sign boards, deals in wide range of sign boards like acp sign boards, stainless steel sign boards, 3d sign boards, engraved sign boards, flex sign boards and so on.
Engine Coolant (Popularity: ): A well reckoned as one of the distinguished manufactures and suppliers of coolants from Maharashtra providing ahuge range of coolents like antifreeze coolant, engine coolant, metal corrosion inhibitor and corrosion inhibitor and many more
Ilex Oncology, Inc. (Popularity: ): Develops pharmaceuticals relating to anti-cancer therapeutics. Includes product portfolio, with clinical trials and licensing details, conferences, international careers from San Antonio, Texas. (Nasdaq: ILXO).
Separation Agreement (Popularity: ): Separation agreements - Net Lawman IE provides comprehensive separation agreement for legal separation. DIY separation agreements in plain English. There is no requirement to formally record the agreement you and your former partner reach.